225 FRANKLIN STREET, BOSTON, MA
Investor Presentation
Palvella Therapeutics Enters Underwriting Agreement for 1.6M Shares
Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
Earnings Release
Palvella Therapeutics Reports Positive Phase 2 Results for QTORIN™ in Treating Rare Genetic Disease
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Notice of Proposed Sale of Securities
Correspondence
Submission Upload